ResMed's June 2026 CDI Total Surges to 594 Million Amid Significant ASX-NYSE Security Transfers

ResMed’s June 2026 Appendix 4A Shows CDI Count Climbs to 594 Million Due to Net Transfers from NYSE

On 3 July 2026, ResMed Inc lodged its Appendix 4A with the ASX, reporting its securities position as of 30 June 2026. The total CDIs issued over quoted securities, trading under ASX code RMD with a 10:1 CDI-to-share ratio, increased to 594,001,760 from 571,167,440 at the end of May 2026. This represents a net monthly increase of 22,834,320 CDIs.

The principal factor behind this rise was the net transfer of securities from common stock on the NYSE into ASX-listed CDIs. ResMed’s dual-listed structure allows investors to hold economic exposure either through ASX CDIs or NYSE common stock. These transfers account for much of the monthly fluctuation in CDI numbers. The nearly 22.8 million CDIs transferred in June indicate significant investor activity shifting equity representation from the NYSE to the ASX.

Understanding ResMed’s 10:1 CDI Ratio Connecting ASX Investors to NYSE Common Stock

ResMed is a US-incorporated company primarily listed on the NYSE under ticker RMD. It holds a secondary foreign-exempt listing on the ASX via CHESS Depositary Interests, where each CDI represents one-tenth of a ResMed common share. Thus, the 594,001,760 CDIs outstanding at June’s end correspond to approximately 59.4 million common stock equivalents when applying the 10:1 ratio.

This CDI structure enables Australian investors to access ResMed shares in Australian dollars on the ASX without direct NYSE participation. Many large US-headquartered companies with significant Australian investor bases employ this mechanism. ResMed’s monthly Appendix 4A filings provide transparency on CDI issuance and shifts between the ASX and NYSE, aiding investors monitoring local market liquidity and float.

Declines in RMDAB and RMDAA Securities Reflect CDI Conversion and NYSE Buybacks

While ASX CDI numbers rose in June 2026, NYSE-listed securities declined. The RMDAB security, representing the 10:1 CDI equivalent of NYSE common stock, fell by 24,648,440 to 848,393,870 at June’s close, down from 873,042,310 in May. Similarly, RMDAA common stock decreased by 2,464,844 to 84,839,387 from 87,304,231.

ResMed attributed these changes to net transfers between ASX CDIs and NYSE common stock, issuance of new shares on the NYSE from stock options, restricted stock units (RSUs), employee stock purchase plan (ESPP) activity, and share repurchases on the NYSE. Despite new shares issued for employee equity plans, share repurchases reduced the overall common stock pool. The exact volume of shares repurchased in June was not disclosed in this update.

Employee Equity Programs Continue to Impact Monthly Share Movements

ResMed’s monthly CDI reports consistently note new share issuances under its Incentive Award Plan and Employee Stock Purchase Plan, which grant stock options, RSUs, and discounted stock purchases to employees globally. When these awards vest or are exercised, new shares are issued on the NYSE, affecting monthly securities counts.

The June 2026 update confirms such issuances occurred but does not separately quantify them. This aligns with ResMed’s historical reporting approach in Appendix 4A filings. Investors interested in dilution from employee equity plans should consult the company’s quarterly and annual reports for detailed disclosures on RSU and option activity.

NYSE Share Repurchase Activity Lowers Outstanding Common Stock in June 2026

Notably, the June 2026 Appendix 4A confirms ongoing share repurchases by ResMed on the NYSE. Share buybacks are a common capital management strategy used by large US firms to return cash to shareholders and offset dilution from employee equity issuances. The decline in both RMDAA and RMDAB common stock despite new share issuances suggests repurchases exceeded new shares issued during June.

The company did not specify the number of shares repurchased or remaining repurchase capacity in this update. Investors seeking detailed buyback information should refer to ResMed’s separate disclosures and US Securities and Exchange Commission filings, which provide quarterly buyback data.

Implications of the Net Shift Toward ASX-Listed CDIs for Australian Investors

The net addition of over 22.8 million CDIs on the ASX in June 2026 is among the larger monthly transfers in recent filings, though no direct historical comparison was provided. This net increase, paired with a decline in NYSE securities, may reflect Australian institutional or retail investors converting NYSE-held common stock into ASX CDIs for reasons such as local settlement convenience, tax considerations, or portfolio management.

These transfers do not represent new capital inflows but rather a conversion of existing holdings. The total economic interest remains unchanged for investors transferring between formats. However, a larger ASX CDI pool could enhance trading liquidity in RMD CDIs locally. The immediate effect on share price was not evident from available data.

ResMed’s Combined Share Count Across ASX and NYSE After June 2026 Adjustments

Aggregating June 2026 data reveals ResMed’s equity distribution: 594,001,760 CDIs on the ASX (equivalent to about 59.4 million common shares), 848,393,870 RMDAB securities on the NYSE (CDI equivalents), and 84,839,387 RMDAA common shares on the NYSE. It is important to recognize that RMDAB and RMDAA represent different forms of underlying equity, and official total shares outstanding should be confirmed via ResMed’s SEC filings.

The company did not provide a consolidated total share count or guidance on future CDI movements or buybacks in this update. Upcoming quarterly earnings and SEC filings are expected to clarify total diluted share counts and capital management activities.

Regulatory Requirements for Monthly CDI Reporting by Foreign ASX-Listed Companies

As a foreign entity with a secondary ASX listing, ResMed must comply with ASX Listing Rules requiring monthly Appendix 4A filings disclosing CDI counts and material changes. This ensures ASX investors have timely insight into securities underlying their CDI holdings, given the primary register and share issuance occur on an overseas exchange.

The Appendix 4A also mandates that if the CDI count surpasses previously paid listing fee thresholds, the company applies for quotation of the additional securities under ASX Listing Rule obligations. ResMed’s June 2026 filing triggered this process due to the CDI increase of 22,834,320. This is a routine regulatory procedure and does not involve new capital raising or issuance to external investors.

Investors Should Track ResMed’s Monthly and Quarterly Capital Structure Updates

Investors monitoring ResMed’s capital structure will find the monthly Appendix 4A reports valuable for tracking equity distribution between ASX and NYSE. The June 2026 data highlights a notable acceleration in ASX CDI volume driven by net transfers from NYSE common stock. Whether this trend continues will be evident in the next filing anticipated in early August 2026.

Additionally, ResMed’s upcoming quarterly earnings release, aligned with US reporting requirements, is expected to provide updated commentary on share repurchases, employee equity plan activity, and capital allocation strategies. As a major player in the global sleep apnea and respiratory care market and one of the largest ASX-listed companies by market cap, ResMed’s CDI structure and capital management remain closely watched by Australian institutional and retail investors.